Orsoten slim caps. 60 mg 84 pcs

$30.44

Orsoten slim caps. 60 mg 84 pcs

Quantity:

Description

Composition
Active substance:
1 capsule contains: semifinished-beads 112.80 mg 60.00 mg orlistat comprises adjuvant semi-granules: microcrystalline cellulose 52.80 mg] ;.
Excipients:
Cellulose microcrystalline 22.20 mg housing: titanium dioxide (E171) 0,58 mg, 28.22 mg gelatin cap: titanium dioxide (E171) 0,19 mg, 18.97 mg of gelatin, iron oxide yellow dye (E172) 0, 04 mg.
Description:
Hard gelatin capsules № 3, the housing white capsule cap capsules light yellow color. The contents of capsules: micropellets or microgranules and a mixture of a powder of white or almost white color.
Presence of compacted agglomerates easily crumbling under pressure.
Product form:
Capsules, 60 mg.
21 capsules in blisters from the composite material of PVC / PVDC and aluminum foil. 2 or 4 blisters together with instructions for use placed in a pile of cardboard.
Contraindications
Increased sensitivity to orlistat or to any component of the drug; chronic malabsorption syndrome; cholestasis; simultaneous application of cyclosporin; simultaneous application of anticoagulants (warfarin); simultaneous application of sitagliptin; pregnancy and lactation; age 18 years.
Dosage
60 mg
Indications
Reduction of excessive body weight in adult patients (18 years or older) with a body mass index (BMI) over 28 kg / m2. It applies only in conjunction with hypocaloric diet moderately containing not more than 30% of daily energy as fat.
Interaction with other drugs
cyclosporine
In several studies on interaction of cyclosporin drug, when applied simultaneously with orlistat, has been reported to decrease the concentration of cyclosporine in the blood plasma. This could potentially lead to a decrease of immunosuppressive efficacy of the latter. Simultaneous use of the drug cyclosporine and slim Orsoten® contraindicated.
indirect anticoagulants
With the simultaneous use of warfarin or other anticoagulants oral preparation with Orsoten® slim INR values ​​may vary.
Fat-soluble vitamins
Admission Orsoten® slim drug can potentially impair the absorption of fat-soluble vitamins (A, D, E, K and beta-carotene).
acarbose
Given the lack of studies investigating the pharmacokinetic interaction it is not recommended to use the drug Orsoten® slim simultaneously with acarbose.
amiodarone
While the use of orlistat marked decrease in the concentration of amiodarone in blood plasma after a single reception. The clinical relevance of this effect in patients receiving amiodarone, is unclear. Simultaneous use of the drug Orsoten® slim and amiodarone is possible only on doctor’s advice.
The lack of interaction
Orlistat does not interact with amitriptyline, phenytoin, fluoxetine, sibutramine, phentermine, atorvastatin, pravastatin, fibrates, biguanides, digoxin, nifedipine, losartan and ethanol.
Overdose
When applied in a dose of orlistat 800 mg dose and the dose of 400 mg three times daily for 15 days as in individuals with normal body weight and in obese patients, revealed no significant HF. When applied in a dose of orlistat is 240 mg three times a day were observed for 6 months, dose-dependent increase in the frequency HF.
In most reported cases of overdose of orlistat in the Post-registration period indicate HP are either absent or they are similar to those which can be after taking recommended doses of the drug.
In case of overdose, consult your doctor. When a large overdose of orlistat is recommended for patient observation for 24 hours. According to preclinical and clinical trials of systemic effects associated with the inhibition of lipase as a rule, quickly reversible.
pharmachologic effect
Pharmacological group:
Lipase inhibitor of the gastrointestinal tract.
Pharmacodynamics:
Orlistat is a potent specific inhibitor of gastrointestinal lipases prolonged action. He shows his therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of gastric and pancreatic lipases. Inactivated enzyme loses the ability to hydrolyze dietary fats (triglycerides) in absorbable free fatty acids and monoglycerides. Unsplit triglycerides are not absorbed, which reduces the amount of calories metabolized by the body, and to reduce body weight. The therapeutic effect of the drug carried thereby without absorption into the systemic circulation. According to the results of clinical trials orlistat received a daily dose of 60 mg 3 times daily blocks the absorption of about 25% fat, included in the daily diet.
Along with a reduction in body weight, with chronic administration of orlistat at a dose of 60 mg marked decrease indicators such as waist circumference, the concentration of total cholesterol (TC) and the concentration of cholesterol low density lipoprotein (LDL) in the blood plasma. After 6 months therapy with orlistat 60mg average total cholesterol concentration in blood plasma decreases on average by 2.4%, LDL – 3.5%. Waist circumference after 6 months taking the drug decreases, on average, 4.5 cm.
Pharmacokinetics:
Suction
Drug absorption is minimal.
breeding
About 97% of an oral dose excreted through the gut, 83% of this amount – unchanged.
Excretion of orlistat and its metabolites kidney is less than 2% of the dose. The drug is completely eliminated after 3-5 days. Excretion of orlistat as the volunteers of normal weight and obese patients similarly.
Pregnancy and breast-feeding
Orsoten® slim drug should not be used during pregnancy due to lack of reliable clinical evidence to support its safe use.
Not applicable if orlistat penetrates into breast milk, and therefore, the preparation Orsoten® slim during breast-feeding is not recommended.
Conditions of supply of pharmacies
Without a prescription.
side effects
Adverse reactions (HP) while taking the drug Orsoten® slim usually observed from the gastrointestinal tract (GIT) and pharmacological effect caused by the drug.
Classification of the incidence of HP recommended by the World Health Organization (WHO): very common> 1/10, often by> 1/100 to 1/1000 to 1/10000 to
Below is the frequency of the HF from the various organs and systems.
Clinical studies investigating the use of orlistat, 60 mg duration of 18 to 24 months installed HP from the gastrointestinal tract, which was generally reversible and lungs. they usually manifested at the beginning of treatment. Compliance with a diet low in fat reduces the risk of such reactions.
On the part of the digestive tract: very common: oily discharge from the rectum, discharge of gas with a certain amount of discharge, urgency to defecate, steatorrhea; common: abdominal pain, fecal incontinence, loose stools, more frequent bowel movements.
As a rule, these HP are mild and transient. They occur early in treatment (within the first 3 months of treatment), and the majority of patients did not have more than one episode of such reactions.
From the side of hematopoiesis: reduction in the concentration of prothrombin and increase in the international normalized ratio (INR) in the blood plasma of patients taking orlistat in conjunction with indirect anticoagulants.
On the part of the digestive tract: a slight bleeding from the rectum, diverticulitis.
Skin and subcutaneous tissue: bullous rash.
Immune system: Hypersensitivity reactions, including skin itching, skin rash, urticaria, angioedema, bronchoconstriction, and anaphylaxis.
Of the liver and biliary tract: cholelithiasis, hepatitis, increased activity of “hepatic” transaminases and alkaline phosphatase in the blood plasma.
special instructions
Diet and exercise are an integral part of the program of weight loss. It is recommended to start the diet program and exercise prior to therapy with Orsoten® slim.
During dosing Orsoten® slim must adhere fractional balanced, moderately hypocaloric feeding, with a fat content not exceeding 30% of the daily caloric intake (for example, when 2000 kcal diet / day of fat intake should not exceed 66 g / day). It should adhere to the received recommendations on diet and physical activity, both during and after termination of ingestion.
Use of the drug Orsoten® slim increases the fat content in the feces after only 24-48 hours after the beginning of reception. After termination of the drug Orsoten® slim fat content in feces is usually returned to baseline within 48-72 hours.
Compliance with a diet low in fat reduces the risk of
HP from the gastrointestinal tract.
Orlistat may potentially impair the absorption of fat-soluble vitamins (A, D, E, K and beta-carotene). The overwhelming majority of patients treated with orlistat during the four-year clinical studies concentrations of vitamins A, D, E, K and beta-carotene were within the normal range. For prophylaxis it is recommended to take a multivitamin at night.
Since the weight loss is usually accompanied by improvement of carbohydrate metabolism indices, patients with type 2 diabetes before therapy with Orsoten® slim should consult a doctor and, if necessary to adjust the dose of hypoglycemic drugs.
Decrease in body weight in the treatment may be accompanied by a decrease in blood pressure and total cholesterol concentration in blood plasma. Patients receiving lipid-lowering or antihypertensive drugs should consult a doctor and, if necessary, to carry out correction of the dose of these drugs.
In clinical studies the interaction between oral contraceptives and orlistat were observed. However, orlistat may indirectly reduce the contraceptive bioavailability for oral administration, which can lead to unwanted pregnancy. It is recommended to use additional methods of contraception in the case of acute diarrhea.
Patients suffering from kidney disease, you should consult with your doctor, because it is possible the development of hyperoxaluria and nephropathy.
Patients receiving amiodarone, warfarin or other oral anticoagulants should also consult a physician before treatment with orlistat as possible changes INR indicator.
Patients should stop taking the drug Orsoten® slim and consult a doctor in case of symptoms: icteric staining of the sclera or skin, itching, dark urine, and loss of appetite.
Effect on the ability to drive mechanisms and
Orsoten® slim drug has no effect on ability to drive and use machines.
Storage conditions
At temperatures above 25 C, in the original package.
Keep out of the reach of children.
Dosing and Administration
For adult patients, the recommended dose of the drug Orsoten® slim is 60 mg (1 capsule) three times a day with each main meal in combination with moderately hypocaloric diet low in fat. The capsule should be taken immediately before a meal, during meal time and no later than 1 hour after meals with water. If the meal is passed or if the food does not contain fat, the reception Orsoten® preparation can skip slim.
Within one day can be taken no more than 3 capsules preparation Orsoten® slim.
Orsoten® slim drug should only be taken in recommended doses.
Treatment is recommended no more than 6 months. The obtained results of weight loss are advised to discuss with your doctor. If, after 12 weeks of treatment with the drug Orsoten® slim no reduction in body weight (ie, body weight loss is less than 5% of the original), you need to consult a doctor to decide on the continuation of treatment.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Krka UTS

There are no reviews yet.

Add your review